High-risk PCI facilitated by levosimendan infusion and Impella CP support in ACS cohort-pilot study.

MLA

Turkiewicz, Karol, et al. “High-Risk PCI Facilitated by Levosimendan Infusion and Impella CP Support in ACS Cohort-Pilot Study.” Kardiologia Polska, vol. 82, no. 7–8, 2024, pp. 771–73. EBSCOhost, https://doi.org/10.33963/v.phj.100689.

APA

Turkiewicz, K., Rola, P., Kulczycki, J. J., Włodarczak, S., Jastrzębski, A., Pęcherzewski, M., Furtan, Ł., Barycki, M., Doroszko, A., Włodarczak, A., & Lesiak, M. (2024). High-risk PCI facilitated by levosimendan infusion and Impella CP support in ACS cohort-pilot study. Kardiologia Polska, 82(7–8), 771–773. https://doi.org/10.33963/v.phj.100689

Chicago

Turkiewicz, Karol, Piotr Rola, Jan Jakub Kulczycki, Szymon Włodarczak, Artur Jastrzębski, Maciej Pęcherzewski, Łukasz Furtan, et al. 2024. “High-Risk PCI Facilitated by Levosimendan Infusion and Impella CP Support in ACS Cohort-Pilot Study.” Kardiologia Polska 82 (7–8): 771–73. doi:10.33963/v.phj.100689.